IBDEI093 ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,22218,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22218,1,3,0)
;;=3^Idiopathic Pericarditis,Acute Nonspec
;;^UTILITY(U,$J,358.3,22218,1,4,0)
;;=4^I30.0
;;^UTILITY(U,$J,358.3,22218,2)
;;=^5007157
;;^UTILITY(U,$J,358.3,22219,0)
;;=I34.8^^71^913^6
;;^UTILITY(U,$J,358.3,22219,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22219,1,3,0)
;;=3^Mitral Valve Disorders,Nonrheumatic Other
;;^UTILITY(U,$J,358.3,22219,1,4,0)
;;=4^I34.8
;;^UTILITY(U,$J,358.3,22219,2)
;;=^5007172
;;^UTILITY(U,$J,358.3,22220,0)
;;=I34.0^^71^913^13
;;^UTILITY(U,$J,358.3,22220,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22220,1,3,0)
;;=3^Nonrheumatic Mitral Valve Insufficiency
;;^UTILITY(U,$J,358.3,22220,1,4,0)
;;=4^I34.0
;;^UTILITY(U,$J,358.3,22220,2)
;;=^5007169
;;^UTILITY(U,$J,358.3,22221,0)
;;=I34.9^^71^913^12
;;^UTILITY(U,$J,358.3,22221,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22221,1,3,0)
;;=3^Nonrheumatic Mitral Valve Disorder,Unspec
;;^UTILITY(U,$J,358.3,22221,1,4,0)
;;=4^I34.9
;;^UTILITY(U,$J,358.3,22221,2)
;;=^5007173
;;^UTILITY(U,$J,358.3,22222,0)
;;=I34.2^^71^913^7
;;^UTILITY(U,$J,358.3,22222,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22222,1,3,0)
;;=3^Nonrhematic Mitral Valve Stenosis
;;^UTILITY(U,$J,358.3,22222,1,4,0)
;;=4^I34.2
;;^UTILITY(U,$J,358.3,22222,2)
;;=^5007171
;;^UTILITY(U,$J,358.3,22223,0)
;;=I35.0^^71^913^10
;;^UTILITY(U,$J,358.3,22223,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22223,1,3,0)
;;=3^Nonrheumatic Aortic Valve Stenosis
;;^UTILITY(U,$J,358.3,22223,1,4,0)
;;=4^I35.0
;;^UTILITY(U,$J,358.3,22223,2)
;;=^5007174
;;^UTILITY(U,$J,358.3,22224,0)
;;=I35.1^^71^913^9
;;^UTILITY(U,$J,358.3,22224,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22224,1,3,0)
;;=3^Nonrheumatic Aortic Valve Insufficiency
;;^UTILITY(U,$J,358.3,22224,1,4,0)
;;=4^I35.1
;;^UTILITY(U,$J,358.3,22224,2)
;;=^5007175
;;^UTILITY(U,$J,358.3,22225,0)
;;=I35.2^^71^913^11
;;^UTILITY(U,$J,358.3,22225,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22225,1,3,0)
;;=3^Nonrheumatic Aortic Valve Stenosis w/ Insufficiency
;;^UTILITY(U,$J,358.3,22225,1,4,0)
;;=4^I35.2
;;^UTILITY(U,$J,358.3,22225,2)
;;=^5007176
;;^UTILITY(U,$J,358.3,22226,0)
;;=I35.9^^71^913^8
;;^UTILITY(U,$J,358.3,22226,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22226,1,3,0)
;;=3^Nonrheumatic Aortic Valve Disorder,Unspec
;;^UTILITY(U,$J,358.3,22226,1,4,0)
;;=4^I35.9
;;^UTILITY(U,$J,358.3,22226,2)
;;=^5007178
;;^UTILITY(U,$J,358.3,22227,0)
;;=I38.^^71^913^4
;;^UTILITY(U,$J,358.3,22227,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22227,1,3,0)
;;=3^Endocarditis,Valve Unspec
;;^UTILITY(U,$J,358.3,22227,1,4,0)
;;=4^I38.
;;^UTILITY(U,$J,358.3,22227,2)
;;=^40327
;;^UTILITY(U,$J,358.3,22228,0)
;;=I05.0^^71^913^18
;;^UTILITY(U,$J,358.3,22228,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22228,1,3,0)
;;=3^Rheumatic Mitral Stenosis
;;^UTILITY(U,$J,358.3,22228,1,4,0)
;;=4^I05.0
;;^UTILITY(U,$J,358.3,22228,2)
;;=^5007041
;;^UTILITY(U,$J,358.3,22229,0)
;;=I05.8^^71^913^19
;;^UTILITY(U,$J,358.3,22229,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22229,1,3,0)
;;=3^Rheumatic Mitral Valve Disease NEC
;;^UTILITY(U,$J,358.3,22229,1,4,0)
;;=4^I05.8
;;^UTILITY(U,$J,358.3,22229,2)
;;=^5007043
;;^UTILITY(U,$J,358.3,22230,0)
;;=I05.9^^71^913^20
;;^UTILITY(U,$J,358.3,22230,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22230,1,3,0)
;;=3^Rheumatic Mitral Valve Disease,Unspec
;;^UTILITY(U,$J,358.3,22230,1,4,0)
;;=4^I05.9
;;^UTILITY(U,$J,358.3,22230,2)
;;=^5007044
;;^UTILITY(U,$J,358.3,22231,0)
;;=I07.1^^71^913^21
;;^UTILITY(U,$J,358.3,22231,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22231,1,3,0)
;;=3^Rheumatic Tricuspid Insufficiency
;;^UTILITY(U,$J,358.3,22231,1,4,0)
;;=4^I07.1
;;^UTILITY(U,$J,358.3,22231,2)
;;=^5007048
;;^UTILITY(U,$J,358.3,22232,0)
;;=I07.9^^71^913^22
;;^UTILITY(U,$J,358.3,22232,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22232,1,3,0)
;;=3^Rheumatic Tricuspid Valve Disease,Unspec
;;^UTILITY(U,$J,358.3,22232,1,4,0)
;;=4^I07.9
;;^UTILITY(U,$J,358.3,22232,2)
;;=^5007051
;;^UTILITY(U,$J,358.3,22233,0)
;;=I08.0^^71^913^16
;;^UTILITY(U,$J,358.3,22233,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22233,1,3,0)
;;=3^Rheumatic Disorders of Mitral & Aortic Valves
;;^UTILITY(U,$J,358.3,22233,1,4,0)
;;=4^I08.0
;;^UTILITY(U,$J,358.3,22233,2)
;;=^5007052
;;^UTILITY(U,$J,358.3,22234,0)
;;=I09.89^^71^913^17
;;^UTILITY(U,$J,358.3,22234,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22234,1,3,0)
;;=3^Rheumatic Heart Diseases NEC
;;^UTILITY(U,$J,358.3,22234,1,4,0)
;;=4^I09.89
;;^UTILITY(U,$J,358.3,22234,2)
;;=^5007060
;;^UTILITY(U,$J,358.3,22235,0)
;;=I47.1^^71^913^24
;;^UTILITY(U,$J,358.3,22235,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22235,1,3,0)
;;=3^Supraventricular Tachycardia
;;^UTILITY(U,$J,358.3,22235,1,4,0)
;;=4^I47.1
;;^UTILITY(U,$J,358.3,22235,2)
;;=^5007223
;;^UTILITY(U,$J,358.3,22236,0)
;;=I48.0^^71^913^15
;;^UTILITY(U,$J,358.3,22236,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22236,1,3,0)
;;=3^Paroxysmal Atrial Fibrillation
;;^UTILITY(U,$J,358.3,22236,1,4,0)
;;=4^I48.0
;;^UTILITY(U,$J,358.3,22236,2)
;;=^90473
;;^UTILITY(U,$J,358.3,22237,0)
;;=I49.5^^71^913^23
;;^UTILITY(U,$J,358.3,22237,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22237,1,3,0)
;;=3^Sick Sinus Syndrome
;;^UTILITY(U,$J,358.3,22237,1,4,0)
;;=4^I49.5
;;^UTILITY(U,$J,358.3,22237,2)
;;=^110404
;;^UTILITY(U,$J,358.3,22238,0)
;;=I49.8^^71^913^3
;;^UTILITY(U,$J,358.3,22238,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22238,1,3,0)
;;=3^Cardiac Arrhythmias
;;^UTILITY(U,$J,358.3,22238,1,4,0)
;;=4^I49.8
;;^UTILITY(U,$J,358.3,22238,2)
;;=^5007236
;;^UTILITY(U,$J,358.3,22239,0)
;;=I49.9^^71^913^2
;;^UTILITY(U,$J,358.3,22239,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22239,1,3,0)
;;=3^Cardiac Arrhythmia,Unspec
;;^UTILITY(U,$J,358.3,22239,1,4,0)
;;=4^I49.9
;;^UTILITY(U,$J,358.3,22239,2)
;;=^5007237
;;^UTILITY(U,$J,358.3,22240,0)
;;=R00.1^^71^913^1
;;^UTILITY(U,$J,358.3,22240,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22240,1,3,0)
;;=3^Bradycardia,Unspec
;;^UTILITY(U,$J,358.3,22240,1,4,0)
;;=4^R00.1
;;^UTILITY(U,$J,358.3,22240,2)
;;=^5019164
;;^UTILITY(U,$J,358.3,22241,0)
;;=I34.1^^71^913^14
;;^UTILITY(U,$J,358.3,22241,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22241,1,3,0)
;;=3^Nonrheumatic Mitral Valve Prolapse
;;^UTILITY(U,$J,358.3,22241,1,4,0)
;;=4^I34.1
;;^UTILITY(U,$J,358.3,22241,2)
;;=^5007170
;;^UTILITY(U,$J,358.3,22242,0)
;;=D68.4^^71^914^1
;;^UTILITY(U,$J,358.3,22242,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22242,1,3,0)
;;=3^Acquired Coagulation Factor Deficiency
;;^UTILITY(U,$J,358.3,22242,1,4,0)
;;=4^D68.4
;;^UTILITY(U,$J,358.3,22242,2)
;;=^2235
;;^UTILITY(U,$J,358.3,22243,0)
;;=D59.9^^71^914^2
;;^UTILITY(U,$J,358.3,22243,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22243,1,3,0)
;;=3^Acquired Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,22243,1,4,0)
;;=4^D59.9
;;^UTILITY(U,$J,358.3,22243,2)
;;=^5002330
;;^UTILITY(U,$J,358.3,22244,0)
;;=C91.00^^71^914^5
;;^UTILITY(U,$J,358.3,22244,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22244,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,22244,1,4,0)
;;=4^C91.00
;;^UTILITY(U,$J,358.3,22244,2)
;;=^5001762
;;^UTILITY(U,$J,358.3,22245,0)
;;=C91.01^^71^914^4
;;^UTILITY(U,$J,358.3,22245,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22245,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,22245,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,22245,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,22246,0)
;;=C92.01^^71^914^7
;;^UTILITY(U,$J,358.3,22246,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22246,1,3,0)
;;=3^Acute Myeloblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,22246,1,4,0)
;;=4^C92.01
;;^UTILITY(U,$J,358.3,22246,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,22247,0)
;;=C92.00^^71^914^8
;;^UTILITY(U,$J,358.3,22247,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22247,1,3,0)
;;=3^Acute Myeloblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,22247,1,4,0)
;;=4^C92.00
;;^UTILITY(U,$J,358.3,22247,2)
;;=^5001789
;;^UTILITY(U,$J,358.3,22248,0)
;;=C92.61^^71^914^9
;;^UTILITY(U,$J,358.3,22248,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22248,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
;;^UTILITY(U,$J,358.3,22248,1,4,0)
;;=4^C92.61
;;^UTILITY(U,$J,358.3,22248,2)
;;=^5001808
;;^UTILITY(U,$J,358.3,22249,0)
;;=C92.60^^71^914^10
;;^UTILITY(U,$J,358.3,22249,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22249,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
;;^UTILITY(U,$J,358.3,22249,1,4,0)
;;=4^C92.60
;;^UTILITY(U,$J,358.3,22249,2)
;;=^5001807
;;^UTILITY(U,$J,358.3,22250,0)
;;=C92.A1^^71^914^11
;;^UTILITY(U,$J,358.3,22250,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22250,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
;;^UTILITY(U,$J,358.3,22250,1,4,0)
;;=4^C92.A1
;;^UTILITY(U,$J,358.3,22250,2)
;;=^5001814
;;^UTILITY(U,$J,358.3,22251,0)
;;=C92.A0^^71^914^12
;;^UTILITY(U,$J,358.3,22251,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22251,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
;;^UTILITY(U,$J,358.3,22251,1,4,0)
;;=4^C92.A0
;;^UTILITY(U,$J,358.3,22251,2)
;;=^5001813
;;^UTILITY(U,$J,358.3,22252,0)
;;=C92.51^^71^914^13
;;^UTILITY(U,$J,358.3,22252,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22252,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,22252,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,22252,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,22253,0)
;;=C92.50^^71^914^14
;;^UTILITY(U,$J,358.3,22253,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22253,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,22253,1,4,0)
;;=4^C92.50
;;^UTILITY(U,$J,358.3,22253,2)
;;=^5001804
;;^UTILITY(U,$J,358.3,22254,0)
;;=C94.40^^71^914^17
;;^UTILITY(U,$J,358.3,22254,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22254,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
;;^UTILITY(U,$J,358.3,22254,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,22254,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,22255,0)
;;=C94.42^^71^914^15
;;^UTILITY(U,$J,358.3,22255,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22255,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
;;^UTILITY(U,$J,358.3,22255,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,22255,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,22256,0)
;;=C94.41^^71^914^16
;;^UTILITY(U,$J,358.3,22256,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22256,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
;;^UTILITY(U,$J,358.3,22256,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,22256,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,22257,0)
;;=D62.^^71^914^18
;;^UTILITY(U,$J,358.3,22257,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22257,1,3,0)
;;=3^Acute Posthemorrhagic Anemia
;;^UTILITY(U,$J,358.3,22257,1,4,0)
;;=4^D62.
;;^UTILITY(U,$J,358.3,22257,2)
;;=^267986
;;^UTILITY(U,$J,358.3,22258,0)
;;=C92.41^^71^914^19
;;^UTILITY(U,$J,358.3,22258,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22258,1,3,0)
;;=3^Acute Promyelocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,22258,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,22258,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,22259,0)
;;=C92.40^^71^914^20
;;^UTILITY(U,$J,358.3,22259,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22259,1,3,0)
;;=3^Acute Promyelocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,22259,1,4,0)
;;=4^C92.40
;;^UTILITY(U,$J,358.3,22259,2)
;;=^5001801
;;^UTILITY(U,$J,358.3,22260,0)
;;=D56.0^^71^914^21
;;^UTILITY(U,$J,358.3,22260,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22260,1,3,0)
;;=3^Alpha Thalassemia
;;^UTILITY(U,$J,358.3,22260,1,4,0)
;;=4^D56.0
;;^UTILITY(U,$J,358.3,22260,2)
;;=^340494
;;^UTILITY(U,$J,358.3,22261,0)
;;=D63.1^^71^914^23
;;^UTILITY(U,$J,358.3,22261,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22261,1,3,0)
;;=3^Anemia in Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,22261,1,4,0)
;;=4^D63.1
;;^UTILITY(U,$J,358.3,22261,2)
;;=^332908
;;^UTILITY(U,$J,358.3,22262,0)
;;=D63.0^^71^914^24
;;^UTILITY(U,$J,358.3,22262,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22262,1,3,0)
;;=3^Anemia in Neoplastic Disease
;;^UTILITY(U,$J,358.3,22262,1,4,0)
;;=4^D63.0
;;^UTILITY(U,$J,358.3,22262,2)
;;=^321978
;;^UTILITY(U,$J,358.3,22263,0)
;;=D63.8^^71^914^22
;;^UTILITY(U,$J,358.3,22263,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22263,1,3,0)
;;=3^Anemia in Chronic Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,22263,1,4,0)
;;=4^D63.8
;;^UTILITY(U,$J,358.3,22263,2)
;;=^5002343
;;^UTILITY(U,$J,358.3,22264,0)
;;=C22.3^^71^914^27
;;^UTILITY(U,$J,358.3,22264,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22264,1,3,0)
;;=3^Angiosarcoma of Liver
;;^UTILITY(U,$J,358.3,22264,1,4,0)
;;=4^C22.3
;;^UTILITY(U,$J,358.3,22264,2)
;;=^5000936
;;^UTILITY(U,$J,358.3,22265,0)
;;=D61.9^^71^914^28
;;^UTILITY(U,$J,358.3,22265,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22265,1,3,0)
;;=3^Aplastic Anemia,Unspec
;;^UTILITY(U,$J,358.3,22265,1,4,0)
;;=4^D61.9
;;^UTILITY(U,$J,358.3,22265,2)
;;=^5002342
;;^UTILITY(U,$J,358.3,22266,0)
;;=D56.1^^71^914^34
;;^UTILITY(U,$J,358.3,22266,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22266,1,3,0)
;;=3^Beta Thalassemia
;;^UTILITY(U,$J,358.3,22266,1,4,0)
;;=4^D56.1
;;^UTILITY(U,$J,358.3,22266,2)
;;=^340495
;;^UTILITY(U,$J,358.3,22267,0)
;;=C83.79^^71^914^36
;;^UTILITY(U,$J,358.3,22267,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22267,1,3,0)
;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,22267,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,22267,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,22268,0)
;;=C83.70^^71^914^37
;;^UTILITY(U,$J,358.3,22268,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22268,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,22268,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,22268,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,22269,0)
;;=D09.0^^71^914^44
;;^UTILITY(U,$J,358.3,22269,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22269,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,22269,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,22269,2)
;;=^267742
;;^UTILITY(U,$J,358.3,22270,0)
;;=D06.9^^71^914^45
;;^UTILITY(U,$J,358.3,22270,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22270,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,22270,1,4,0)
;;=4^D06.9
;;^UTILITY(U,$J,358.3,22270,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,22271,0)
;;=D06.0^^71^914^47
;;^UTILITY(U,$J,358.3,22271,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22271,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,22271,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,22271,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,22272,0)
;;=D06.1^^71^914^48
;;^UTILITY(U,$J,358.3,22272,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22272,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,22272,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,22272,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,22273,0)
;;=D06.7^^71^914^46
;;^UTILITY(U,$J,358.3,22273,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22273,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,22273,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,22273,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,22274,0)
;;=D04.9^^71^914^49
;;^UTILITY(U,$J,358.3,22274,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22274,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,22274,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,22274,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,22275,0)
;;=C91.11^^71^914^52
;;^UTILITY(U,$J,358.3,22275,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22275,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,22275,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,22275,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,22276,0)
;;=C91.10^^71^914^53
;;^UTILITY(U,$J,358.3,22276,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22276,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,22276,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,22276,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,22277,0)
;;=C92.11^^71^914^54
;;^UTILITY(U,$J,358.3,22277,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22277,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,22277,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,22277,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,22278,0)
;;=C92.10^^71^914^55
;;^UTILITY(U,$J,358.3,22278,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22278,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,22278,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,22278,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,22279,0)
;;=D47.1^^71^914^56
;;^UTILITY(U,$J,358.3,22279,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22279,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,22279,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,22279,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,22280,0)
;;=C82.69^^71^914^57
;;^UTILITY(U,$J,358.3,22280,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22280,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,22280,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,22280,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,22281,0)
;;=C82.60^^71^914^58
;;^UTILITY(U,$J,358.3,22281,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22281,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,22281,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,22281,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,22282,0)
;;=D56.2^^71^914^59
;;^UTILITY(U,$J,358.3,22282,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22282,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,22282,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,22282,2)
;;=^340496
;;^UTILITY(U,$J,358.3,22283,0)
;;=D75.9^^71^914^60
;;^UTILITY(U,$J,358.3,22283,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22283,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,22283,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,22283,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,22284,0)
;;=D59.0^^71^914^63
;;^UTILITY(U,$J,358.3,22284,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22284,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,22284,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,22284,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,22285,0)
;;=D59.2^^71^914^64
;;^UTILITY(U,$J,358.3,22285,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22285,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI093 19757 printed Sep 23, 2025@19:20:02 Page 2
IBDEI093 ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,22218,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,22218,1,3,0)
+4 ;;=3^Idiopathic Pericarditis,Acute Nonspec
+5 ;;^UTILITY(U,$J,358.3,22218,1,4,0)
+6 ;;=4^I30.0
+7 ;;^UTILITY(U,$J,358.3,22218,2)
+8 ;;=^5007157
+9 ;;^UTILITY(U,$J,358.3,22219,0)
+10 ;;=I34.8^^71^913^6
+11 ;;^UTILITY(U,$J,358.3,22219,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,22219,1,3,0)
+14 ;;=3^Mitral Valve Disorders,Nonrheumatic Other
+15 ;;^UTILITY(U,$J,358.3,22219,1,4,0)
+16 ;;=4^I34.8
+17 ;;^UTILITY(U,$J,358.3,22219,2)
+18 ;;=^5007172
+19 ;;^UTILITY(U,$J,358.3,22220,0)
+20 ;;=I34.0^^71^913^13
+21 ;;^UTILITY(U,$J,358.3,22220,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,22220,1,3,0)
+24 ;;=3^Nonrheumatic Mitral Valve Insufficiency
+25 ;;^UTILITY(U,$J,358.3,22220,1,4,0)
+26 ;;=4^I34.0
+27 ;;^UTILITY(U,$J,358.3,22220,2)
+28 ;;=^5007169
+29 ;;^UTILITY(U,$J,358.3,22221,0)
+30 ;;=I34.9^^71^913^12
+31 ;;^UTILITY(U,$J,358.3,22221,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,22221,1,3,0)
+34 ;;=3^Nonrheumatic Mitral Valve Disorder,Unspec
+35 ;;^UTILITY(U,$J,358.3,22221,1,4,0)
+36 ;;=4^I34.9
+37 ;;^UTILITY(U,$J,358.3,22221,2)
+38 ;;=^5007173
+39 ;;^UTILITY(U,$J,358.3,22222,0)
+40 ;;=I34.2^^71^913^7
+41 ;;^UTILITY(U,$J,358.3,22222,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,22222,1,3,0)
+44 ;;=3^Nonrhematic Mitral Valve Stenosis
+45 ;;^UTILITY(U,$J,358.3,22222,1,4,0)
+46 ;;=4^I34.2
+47 ;;^UTILITY(U,$J,358.3,22222,2)
+48 ;;=^5007171
+49 ;;^UTILITY(U,$J,358.3,22223,0)
+50 ;;=I35.0^^71^913^10
+51 ;;^UTILITY(U,$J,358.3,22223,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,22223,1,3,0)
+54 ;;=3^Nonrheumatic Aortic Valve Stenosis
+55 ;;^UTILITY(U,$J,358.3,22223,1,4,0)
+56 ;;=4^I35.0
+57 ;;^UTILITY(U,$J,358.3,22223,2)
+58 ;;=^5007174
+59 ;;^UTILITY(U,$J,358.3,22224,0)
+60 ;;=I35.1^^71^913^9
+61 ;;^UTILITY(U,$J,358.3,22224,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,22224,1,3,0)
+64 ;;=3^Nonrheumatic Aortic Valve Insufficiency
+65 ;;^UTILITY(U,$J,358.3,22224,1,4,0)
+66 ;;=4^I35.1
+67 ;;^UTILITY(U,$J,358.3,22224,2)
+68 ;;=^5007175
+69 ;;^UTILITY(U,$J,358.3,22225,0)
+70 ;;=I35.2^^71^913^11
+71 ;;^UTILITY(U,$J,358.3,22225,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,22225,1,3,0)
+74 ;;=3^Nonrheumatic Aortic Valve Stenosis w/ Insufficiency
+75 ;;^UTILITY(U,$J,358.3,22225,1,4,0)
+76 ;;=4^I35.2
+77 ;;^UTILITY(U,$J,358.3,22225,2)
+78 ;;=^5007176
+79 ;;^UTILITY(U,$J,358.3,22226,0)
+80 ;;=I35.9^^71^913^8
+81 ;;^UTILITY(U,$J,358.3,22226,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,22226,1,3,0)
+84 ;;=3^Nonrheumatic Aortic Valve Disorder,Unspec
+85 ;;^UTILITY(U,$J,358.3,22226,1,4,0)
+86 ;;=4^I35.9
+87 ;;^UTILITY(U,$J,358.3,22226,2)
+88 ;;=^5007178
+89 ;;^UTILITY(U,$J,358.3,22227,0)
+90 ;;=I38.^^71^913^4
+91 ;;^UTILITY(U,$J,358.3,22227,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,22227,1,3,0)
+94 ;;=3^Endocarditis,Valve Unspec
+95 ;;^UTILITY(U,$J,358.3,22227,1,4,0)
+96 ;;=4^I38.
+97 ;;^UTILITY(U,$J,358.3,22227,2)
+98 ;;=^40327
+99 ;;^UTILITY(U,$J,358.3,22228,0)
+100 ;;=I05.0^^71^913^18
+101 ;;^UTILITY(U,$J,358.3,22228,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,22228,1,3,0)
+104 ;;=3^Rheumatic Mitral Stenosis
+105 ;;^UTILITY(U,$J,358.3,22228,1,4,0)
+106 ;;=4^I05.0
+107 ;;^UTILITY(U,$J,358.3,22228,2)
+108 ;;=^5007041
+109 ;;^UTILITY(U,$J,358.3,22229,0)
+110 ;;=I05.8^^71^913^19
+111 ;;^UTILITY(U,$J,358.3,22229,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,22229,1,3,0)
+114 ;;=3^Rheumatic Mitral Valve Disease NEC
+115 ;;^UTILITY(U,$J,358.3,22229,1,4,0)
+116 ;;=4^I05.8
+117 ;;^UTILITY(U,$J,358.3,22229,2)
+118 ;;=^5007043
+119 ;;^UTILITY(U,$J,358.3,22230,0)
+120 ;;=I05.9^^71^913^20
+121 ;;^UTILITY(U,$J,358.3,22230,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,22230,1,3,0)
+124 ;;=3^Rheumatic Mitral Valve Disease,Unspec
+125 ;;^UTILITY(U,$J,358.3,22230,1,4,0)
+126 ;;=4^I05.9
+127 ;;^UTILITY(U,$J,358.3,22230,2)
+128 ;;=^5007044
+129 ;;^UTILITY(U,$J,358.3,22231,0)
+130 ;;=I07.1^^71^913^21
+131 ;;^UTILITY(U,$J,358.3,22231,1,0)
+132 ;;=^358.31IA^4^2
+133 ;;^UTILITY(U,$J,358.3,22231,1,3,0)
+134 ;;=3^Rheumatic Tricuspid Insufficiency
+135 ;;^UTILITY(U,$J,358.3,22231,1,4,0)
+136 ;;=4^I07.1
+137 ;;^UTILITY(U,$J,358.3,22231,2)
+138 ;;=^5007048
+139 ;;^UTILITY(U,$J,358.3,22232,0)
+140 ;;=I07.9^^71^913^22
+141 ;;^UTILITY(U,$J,358.3,22232,1,0)
+142 ;;=^358.31IA^4^2
+143 ;;^UTILITY(U,$J,358.3,22232,1,3,0)
+144 ;;=3^Rheumatic Tricuspid Valve Disease,Unspec
+145 ;;^UTILITY(U,$J,358.3,22232,1,4,0)
+146 ;;=4^I07.9
+147 ;;^UTILITY(U,$J,358.3,22232,2)
+148 ;;=^5007051
+149 ;;^UTILITY(U,$J,358.3,22233,0)
+150 ;;=I08.0^^71^913^16
+151 ;;^UTILITY(U,$J,358.3,22233,1,0)
+152 ;;=^358.31IA^4^2
+153 ;;^UTILITY(U,$J,358.3,22233,1,3,0)
+154 ;;=3^Rheumatic Disorders of Mitral & Aortic Valves
+155 ;;^UTILITY(U,$J,358.3,22233,1,4,0)
+156 ;;=4^I08.0
+157 ;;^UTILITY(U,$J,358.3,22233,2)
+158 ;;=^5007052
+159 ;;^UTILITY(U,$J,358.3,22234,0)
+160 ;;=I09.89^^71^913^17
+161 ;;^UTILITY(U,$J,358.3,22234,1,0)
+162 ;;=^358.31IA^4^2
+163 ;;^UTILITY(U,$J,358.3,22234,1,3,0)
+164 ;;=3^Rheumatic Heart Diseases NEC
+165 ;;^UTILITY(U,$J,358.3,22234,1,4,0)
+166 ;;=4^I09.89
+167 ;;^UTILITY(U,$J,358.3,22234,2)
+168 ;;=^5007060
+169 ;;^UTILITY(U,$J,358.3,22235,0)
+170 ;;=I47.1^^71^913^24
+171 ;;^UTILITY(U,$J,358.3,22235,1,0)
+172 ;;=^358.31IA^4^2
+173 ;;^UTILITY(U,$J,358.3,22235,1,3,0)
+174 ;;=3^Supraventricular Tachycardia
+175 ;;^UTILITY(U,$J,358.3,22235,1,4,0)
+176 ;;=4^I47.1
+177 ;;^UTILITY(U,$J,358.3,22235,2)
+178 ;;=^5007223
+179 ;;^UTILITY(U,$J,358.3,22236,0)
+180 ;;=I48.0^^71^913^15
+181 ;;^UTILITY(U,$J,358.3,22236,1,0)
+182 ;;=^358.31IA^4^2
+183 ;;^UTILITY(U,$J,358.3,22236,1,3,0)
+184 ;;=3^Paroxysmal Atrial Fibrillation
+185 ;;^UTILITY(U,$J,358.3,22236,1,4,0)
+186 ;;=4^I48.0
+187 ;;^UTILITY(U,$J,358.3,22236,2)
+188 ;;=^90473
+189 ;;^UTILITY(U,$J,358.3,22237,0)
+190 ;;=I49.5^^71^913^23
+191 ;;^UTILITY(U,$J,358.3,22237,1,0)
+192 ;;=^358.31IA^4^2
+193 ;;^UTILITY(U,$J,358.3,22237,1,3,0)
+194 ;;=3^Sick Sinus Syndrome
+195 ;;^UTILITY(U,$J,358.3,22237,1,4,0)
+196 ;;=4^I49.5
+197 ;;^UTILITY(U,$J,358.3,22237,2)
+198 ;;=^110404
+199 ;;^UTILITY(U,$J,358.3,22238,0)
+200 ;;=I49.8^^71^913^3
+201 ;;^UTILITY(U,$J,358.3,22238,1,0)
+202 ;;=^358.31IA^4^2
+203 ;;^UTILITY(U,$J,358.3,22238,1,3,0)
+204 ;;=3^Cardiac Arrhythmias
+205 ;;^UTILITY(U,$J,358.3,22238,1,4,0)
+206 ;;=4^I49.8
+207 ;;^UTILITY(U,$J,358.3,22238,2)
+208 ;;=^5007236
+209 ;;^UTILITY(U,$J,358.3,22239,0)
+210 ;;=I49.9^^71^913^2
+211 ;;^UTILITY(U,$J,358.3,22239,1,0)
+212 ;;=^358.31IA^4^2
+213 ;;^UTILITY(U,$J,358.3,22239,1,3,0)
+214 ;;=3^Cardiac Arrhythmia,Unspec
+215 ;;^UTILITY(U,$J,358.3,22239,1,4,0)
+216 ;;=4^I49.9
+217 ;;^UTILITY(U,$J,358.3,22239,2)
+218 ;;=^5007237
+219 ;;^UTILITY(U,$J,358.3,22240,0)
+220 ;;=R00.1^^71^913^1
+221 ;;^UTILITY(U,$J,358.3,22240,1,0)
+222 ;;=^358.31IA^4^2
+223 ;;^UTILITY(U,$J,358.3,22240,1,3,0)
+224 ;;=3^Bradycardia,Unspec
+225 ;;^UTILITY(U,$J,358.3,22240,1,4,0)
+226 ;;=4^R00.1
+227 ;;^UTILITY(U,$J,358.3,22240,2)
+228 ;;=^5019164
+229 ;;^UTILITY(U,$J,358.3,22241,0)
+230 ;;=I34.1^^71^913^14
+231 ;;^UTILITY(U,$J,358.3,22241,1,0)
+232 ;;=^358.31IA^4^2
+233 ;;^UTILITY(U,$J,358.3,22241,1,3,0)
+234 ;;=3^Nonrheumatic Mitral Valve Prolapse
+235 ;;^UTILITY(U,$J,358.3,22241,1,4,0)
+236 ;;=4^I34.1
+237 ;;^UTILITY(U,$J,358.3,22241,2)
+238 ;;=^5007170
+239 ;;^UTILITY(U,$J,358.3,22242,0)
+240 ;;=D68.4^^71^914^1
+241 ;;^UTILITY(U,$J,358.3,22242,1,0)
+242 ;;=^358.31IA^4^2
+243 ;;^UTILITY(U,$J,358.3,22242,1,3,0)
+244 ;;=3^Acquired Coagulation Factor Deficiency
+245 ;;^UTILITY(U,$J,358.3,22242,1,4,0)
+246 ;;=4^D68.4
+247 ;;^UTILITY(U,$J,358.3,22242,2)
+248 ;;=^2235
+249 ;;^UTILITY(U,$J,358.3,22243,0)
+250 ;;=D59.9^^71^914^2
+251 ;;^UTILITY(U,$J,358.3,22243,1,0)
+252 ;;=^358.31IA^4^2
+253 ;;^UTILITY(U,$J,358.3,22243,1,3,0)
+254 ;;=3^Acquired Hemolytic Anemia,Unspec
+255 ;;^UTILITY(U,$J,358.3,22243,1,4,0)
+256 ;;=4^D59.9
+257 ;;^UTILITY(U,$J,358.3,22243,2)
+258 ;;=^5002330
+259 ;;^UTILITY(U,$J,358.3,22244,0)
+260 ;;=C91.00^^71^914^5
+261 ;;^UTILITY(U,$J,358.3,22244,1,0)
+262 ;;=^358.31IA^4^2
+263 ;;^UTILITY(U,$J,358.3,22244,1,3,0)
+264 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
+265 ;;^UTILITY(U,$J,358.3,22244,1,4,0)
+266 ;;=4^C91.00
+267 ;;^UTILITY(U,$J,358.3,22244,2)
+268 ;;=^5001762
+269 ;;^UTILITY(U,$J,358.3,22245,0)
+270 ;;=C91.01^^71^914^4
+271 ;;^UTILITY(U,$J,358.3,22245,1,0)
+272 ;;=^358.31IA^4^2
+273 ;;^UTILITY(U,$J,358.3,22245,1,3,0)
+274 ;;=3^Acute Lymphoblastic Leukemia,In Remission
+275 ;;^UTILITY(U,$J,358.3,22245,1,4,0)
+276 ;;=4^C91.01
+277 ;;^UTILITY(U,$J,358.3,22245,2)
+278 ;;=^5001763
+279 ;;^UTILITY(U,$J,358.3,22246,0)
+280 ;;=C92.01^^71^914^7
+281 ;;^UTILITY(U,$J,358.3,22246,1,0)
+282 ;;=^358.31IA^4^2
+283 ;;^UTILITY(U,$J,358.3,22246,1,3,0)
+284 ;;=3^Acute Myeloblastic Leukemia,In Remission
+285 ;;^UTILITY(U,$J,358.3,22246,1,4,0)
+286 ;;=4^C92.01
+287 ;;^UTILITY(U,$J,358.3,22246,2)
+288 ;;=^5001790
+289 ;;^UTILITY(U,$J,358.3,22247,0)
+290 ;;=C92.00^^71^914^8
+291 ;;^UTILITY(U,$J,358.3,22247,1,0)
+292 ;;=^358.31IA^4^2
+293 ;;^UTILITY(U,$J,358.3,22247,1,3,0)
+294 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
+295 ;;^UTILITY(U,$J,358.3,22247,1,4,0)
+296 ;;=4^C92.00
+297 ;;^UTILITY(U,$J,358.3,22247,2)
+298 ;;=^5001789
+299 ;;^UTILITY(U,$J,358.3,22248,0)
+300 ;;=C92.61^^71^914^9
+301 ;;^UTILITY(U,$J,358.3,22248,1,0)
+302 ;;=^358.31IA^4^2
+303 ;;^UTILITY(U,$J,358.3,22248,1,3,0)
+304 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
+305 ;;^UTILITY(U,$J,358.3,22248,1,4,0)
+306 ;;=4^C92.61
+307 ;;^UTILITY(U,$J,358.3,22248,2)
+308 ;;=^5001808
+309 ;;^UTILITY(U,$J,358.3,22249,0)
+310 ;;=C92.60^^71^914^10
+311 ;;^UTILITY(U,$J,358.3,22249,1,0)
+312 ;;=^358.31IA^4^2
+313 ;;^UTILITY(U,$J,358.3,22249,1,3,0)
+314 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
+315 ;;^UTILITY(U,$J,358.3,22249,1,4,0)
+316 ;;=4^C92.60
+317 ;;^UTILITY(U,$J,358.3,22249,2)
+318 ;;=^5001807
+319 ;;^UTILITY(U,$J,358.3,22250,0)
+320 ;;=C92.A1^^71^914^11
+321 ;;^UTILITY(U,$J,358.3,22250,1,0)
+322 ;;=^358.31IA^4^2
+323 ;;^UTILITY(U,$J,358.3,22250,1,3,0)
+324 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
+325 ;;^UTILITY(U,$J,358.3,22250,1,4,0)
+326 ;;=4^C92.A1
+327 ;;^UTILITY(U,$J,358.3,22250,2)
+328 ;;=^5001814
+329 ;;^UTILITY(U,$J,358.3,22251,0)
+330 ;;=C92.A0^^71^914^12
+331 ;;^UTILITY(U,$J,358.3,22251,1,0)
+332 ;;=^358.31IA^4^2
+333 ;;^UTILITY(U,$J,358.3,22251,1,3,0)
+334 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
+335 ;;^UTILITY(U,$J,358.3,22251,1,4,0)
+336 ;;=4^C92.A0
+337 ;;^UTILITY(U,$J,358.3,22251,2)
+338 ;;=^5001813
+339 ;;^UTILITY(U,$J,358.3,22252,0)
+340 ;;=C92.51^^71^914^13
+341 ;;^UTILITY(U,$J,358.3,22252,1,0)
+342 ;;=^358.31IA^4^2
+343 ;;^UTILITY(U,$J,358.3,22252,1,3,0)
+344 ;;=3^Acute Myelomonocytic Leukemia,In Remission
+345 ;;^UTILITY(U,$J,358.3,22252,1,4,0)
+346 ;;=4^C92.51
+347 ;;^UTILITY(U,$J,358.3,22252,2)
+348 ;;=^5001805
+349 ;;^UTILITY(U,$J,358.3,22253,0)
+350 ;;=C92.50^^71^914^14
+351 ;;^UTILITY(U,$J,358.3,22253,1,0)
+352 ;;=^358.31IA^4^2
+353 ;;^UTILITY(U,$J,358.3,22253,1,3,0)
+354 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
+355 ;;^UTILITY(U,$J,358.3,22253,1,4,0)
+356 ;;=4^C92.50
+357 ;;^UTILITY(U,$J,358.3,22253,2)
+358 ;;=^5001804
+359 ;;^UTILITY(U,$J,358.3,22254,0)
+360 ;;=C94.40^^71^914^17
+361 ;;^UTILITY(U,$J,358.3,22254,1,0)
+362 ;;=^358.31IA^4^2
+363 ;;^UTILITY(U,$J,358.3,22254,1,3,0)
+364 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
+365 ;;^UTILITY(U,$J,358.3,22254,1,4,0)
+366 ;;=4^C94.40
+367 ;;^UTILITY(U,$J,358.3,22254,2)
+368 ;;=^5001843
+369 ;;^UTILITY(U,$J,358.3,22255,0)
+370 ;;=C94.42^^71^914^15
+371 ;;^UTILITY(U,$J,358.3,22255,1,0)
+372 ;;=^358.31IA^4^2
+373 ;;^UTILITY(U,$J,358.3,22255,1,3,0)
+374 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
+375 ;;^UTILITY(U,$J,358.3,22255,1,4,0)
+376 ;;=4^C94.42
+377 ;;^UTILITY(U,$J,358.3,22255,2)
+378 ;;=^5001845
+379 ;;^UTILITY(U,$J,358.3,22256,0)
+380 ;;=C94.41^^71^914^16
+381 ;;^UTILITY(U,$J,358.3,22256,1,0)
+382 ;;=^358.31IA^4^2
+383 ;;^UTILITY(U,$J,358.3,22256,1,3,0)
+384 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
+385 ;;^UTILITY(U,$J,358.3,22256,1,4,0)
+386 ;;=4^C94.41
+387 ;;^UTILITY(U,$J,358.3,22256,2)
+388 ;;=^5001844
+389 ;;^UTILITY(U,$J,358.3,22257,0)
+390 ;;=D62.^^71^914^18
+391 ;;^UTILITY(U,$J,358.3,22257,1,0)
+392 ;;=^358.31IA^4^2
+393 ;;^UTILITY(U,$J,358.3,22257,1,3,0)
+394 ;;=3^Acute Posthemorrhagic Anemia
+395 ;;^UTILITY(U,$J,358.3,22257,1,4,0)
+396 ;;=4^D62.
+397 ;;^UTILITY(U,$J,358.3,22257,2)
+398 ;;=^267986
+399 ;;^UTILITY(U,$J,358.3,22258,0)
+400 ;;=C92.41^^71^914^19
+401 ;;^UTILITY(U,$J,358.3,22258,1,0)
+402 ;;=^358.31IA^4^2
+403 ;;^UTILITY(U,$J,358.3,22258,1,3,0)
+404 ;;=3^Acute Promyelocytic Leukemia,In Remission
+405 ;;^UTILITY(U,$J,358.3,22258,1,4,0)
+406 ;;=4^C92.41
+407 ;;^UTILITY(U,$J,358.3,22258,2)
+408 ;;=^5001802
+409 ;;^UTILITY(U,$J,358.3,22259,0)
+410 ;;=C92.40^^71^914^20
+411 ;;^UTILITY(U,$J,358.3,22259,1,0)
+412 ;;=^358.31IA^4^2
+413 ;;^UTILITY(U,$J,358.3,22259,1,3,0)
+414 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
+415 ;;^UTILITY(U,$J,358.3,22259,1,4,0)
+416 ;;=4^C92.40
+417 ;;^UTILITY(U,$J,358.3,22259,2)
+418 ;;=^5001801
+419 ;;^UTILITY(U,$J,358.3,22260,0)
+420 ;;=D56.0^^71^914^21
+421 ;;^UTILITY(U,$J,358.3,22260,1,0)
+422 ;;=^358.31IA^4^2
+423 ;;^UTILITY(U,$J,358.3,22260,1,3,0)
+424 ;;=3^Alpha Thalassemia
+425 ;;^UTILITY(U,$J,358.3,22260,1,4,0)
+426 ;;=4^D56.0
+427 ;;^UTILITY(U,$J,358.3,22260,2)
+428 ;;=^340494
+429 ;;^UTILITY(U,$J,358.3,22261,0)
+430 ;;=D63.1^^71^914^23
+431 ;;^UTILITY(U,$J,358.3,22261,1,0)
+432 ;;=^358.31IA^4^2
+433 ;;^UTILITY(U,$J,358.3,22261,1,3,0)
+434 ;;=3^Anemia in Chronic Kidney Disease
+435 ;;^UTILITY(U,$J,358.3,22261,1,4,0)
+436 ;;=4^D63.1
+437 ;;^UTILITY(U,$J,358.3,22261,2)
+438 ;;=^332908
+439 ;;^UTILITY(U,$J,358.3,22262,0)
+440 ;;=D63.0^^71^914^24
+441 ;;^UTILITY(U,$J,358.3,22262,1,0)
+442 ;;=^358.31IA^4^2
+443 ;;^UTILITY(U,$J,358.3,22262,1,3,0)
+444 ;;=3^Anemia in Neoplastic Disease
+445 ;;^UTILITY(U,$J,358.3,22262,1,4,0)
+446 ;;=4^D63.0
+447 ;;^UTILITY(U,$J,358.3,22262,2)
+448 ;;=^321978
+449 ;;^UTILITY(U,$J,358.3,22263,0)
+450 ;;=D63.8^^71^914^22
+451 ;;^UTILITY(U,$J,358.3,22263,1,0)
+452 ;;=^358.31IA^4^2
+453 ;;^UTILITY(U,$J,358.3,22263,1,3,0)
+454 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
+455 ;;^UTILITY(U,$J,358.3,22263,1,4,0)
+456 ;;=4^D63.8
+457 ;;^UTILITY(U,$J,358.3,22263,2)
+458 ;;=^5002343
+459 ;;^UTILITY(U,$J,358.3,22264,0)
+460 ;;=C22.3^^71^914^27
+461 ;;^UTILITY(U,$J,358.3,22264,1,0)
+462 ;;=^358.31IA^4^2
+463 ;;^UTILITY(U,$J,358.3,22264,1,3,0)
+464 ;;=3^Angiosarcoma of Liver
+465 ;;^UTILITY(U,$J,358.3,22264,1,4,0)
+466 ;;=4^C22.3
+467 ;;^UTILITY(U,$J,358.3,22264,2)
+468 ;;=^5000936
+469 ;;^UTILITY(U,$J,358.3,22265,0)
+470 ;;=D61.9^^71^914^28
+471 ;;^UTILITY(U,$J,358.3,22265,1,0)
+472 ;;=^358.31IA^4^2
+473 ;;^UTILITY(U,$J,358.3,22265,1,3,0)
+474 ;;=3^Aplastic Anemia,Unspec
+475 ;;^UTILITY(U,$J,358.3,22265,1,4,0)
+476 ;;=4^D61.9
+477 ;;^UTILITY(U,$J,358.3,22265,2)
+478 ;;=^5002342
+479 ;;^UTILITY(U,$J,358.3,22266,0)
+480 ;;=D56.1^^71^914^34
+481 ;;^UTILITY(U,$J,358.3,22266,1,0)
+482 ;;=^358.31IA^4^2
+483 ;;^UTILITY(U,$J,358.3,22266,1,3,0)
+484 ;;=3^Beta Thalassemia
+485 ;;^UTILITY(U,$J,358.3,22266,1,4,0)
+486 ;;=4^D56.1
+487 ;;^UTILITY(U,$J,358.3,22266,2)
+488 ;;=^340495
+489 ;;^UTILITY(U,$J,358.3,22267,0)
+490 ;;=C83.79^^71^914^36
+491 ;;^UTILITY(U,$J,358.3,22267,1,0)
+492 ;;=^358.31IA^4^2
+493 ;;^UTILITY(U,$J,358.3,22267,1,3,0)
+494 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
+495 ;;^UTILITY(U,$J,358.3,22267,1,4,0)
+496 ;;=4^C83.79
+497 ;;^UTILITY(U,$J,358.3,22267,2)
+498 ;;=^5001600
+499 ;;^UTILITY(U,$J,358.3,22268,0)
+500 ;;=C83.70^^71^914^37
+501 ;;^UTILITY(U,$J,358.3,22268,1,0)
+502 ;;=^358.31IA^4^2
+503 ;;^UTILITY(U,$J,358.3,22268,1,3,0)
+504 ;;=3^Burkitt Lymphoma,Unspec Site
+505 ;;^UTILITY(U,$J,358.3,22268,1,4,0)
+506 ;;=4^C83.70
+507 ;;^UTILITY(U,$J,358.3,22268,2)
+508 ;;=^5001591
+509 ;;^UTILITY(U,$J,358.3,22269,0)
+510 ;;=D09.0^^71^914^44
+511 ;;^UTILITY(U,$J,358.3,22269,1,0)
+512 ;;=^358.31IA^4^2
+513 ;;^UTILITY(U,$J,358.3,22269,1,3,0)
+514 ;;=3^Carcinoma in Situ of Bladder
+515 ;;^UTILITY(U,$J,358.3,22269,1,4,0)
+516 ;;=4^D09.0
+517 ;;^UTILITY(U,$J,358.3,22269,2)
+518 ;;=^267742
+519 ;;^UTILITY(U,$J,358.3,22270,0)
+520 ;;=D06.9^^71^914^45
+521 ;;^UTILITY(U,$J,358.3,22270,1,0)
+522 ;;=^358.31IA^4^2
+523 ;;^UTILITY(U,$J,358.3,22270,1,3,0)
+524 ;;=3^Carcinoma in Situ of Cervix
+525 ;;^UTILITY(U,$J,358.3,22270,1,4,0)
+526 ;;=4^D06.9
+527 ;;^UTILITY(U,$J,358.3,22270,2)
+528 ;;=^5001941
+529 ;;^UTILITY(U,$J,358.3,22271,0)
+530 ;;=D06.0^^71^914^47
+531 ;;^UTILITY(U,$J,358.3,22271,1,0)
+532 ;;=^358.31IA^4^2
+533 ;;^UTILITY(U,$J,358.3,22271,1,3,0)
+534 ;;=3^Carcinoma in Situ of Endocervix
+535 ;;^UTILITY(U,$J,358.3,22271,1,4,0)
+536 ;;=4^D06.0
+537 ;;^UTILITY(U,$J,358.3,22271,2)
+538 ;;=^5001938
+539 ;;^UTILITY(U,$J,358.3,22272,0)
+540 ;;=D06.1^^71^914^48
+541 ;;^UTILITY(U,$J,358.3,22272,1,0)
+542 ;;=^358.31IA^4^2
+543 ;;^UTILITY(U,$J,358.3,22272,1,3,0)
+544 ;;=3^Carcinoma in Situ of Exocervix
+545 ;;^UTILITY(U,$J,358.3,22272,1,4,0)
+546 ;;=4^D06.1
+547 ;;^UTILITY(U,$J,358.3,22272,2)
+548 ;;=^5001939
+549 ;;^UTILITY(U,$J,358.3,22273,0)
+550 ;;=D06.7^^71^914^46
+551 ;;^UTILITY(U,$J,358.3,22273,1,0)
+552 ;;=^358.31IA^4^2
+553 ;;^UTILITY(U,$J,358.3,22273,1,3,0)
+554 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+555 ;;^UTILITY(U,$J,358.3,22273,1,4,0)
+556 ;;=4^D06.7
+557 ;;^UTILITY(U,$J,358.3,22273,2)
+558 ;;=^5001940
+559 ;;^UTILITY(U,$J,358.3,22274,0)
+560 ;;=D04.9^^71^914^49
+561 ;;^UTILITY(U,$J,358.3,22274,1,0)
+562 ;;=^358.31IA^4^2
+563 ;;^UTILITY(U,$J,358.3,22274,1,3,0)
+564 ;;=3^Carcinoma in Situ of Skin
+565 ;;^UTILITY(U,$J,358.3,22274,1,4,0)
+566 ;;=4^D04.9
+567 ;;^UTILITY(U,$J,358.3,22274,2)
+568 ;;=^5001925
+569 ;;^UTILITY(U,$J,358.3,22275,0)
+570 ;;=C91.11^^71^914^52
+571 ;;^UTILITY(U,$J,358.3,22275,1,0)
+572 ;;=^358.31IA^4^2
+573 ;;^UTILITY(U,$J,358.3,22275,1,3,0)
+574 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+575 ;;^UTILITY(U,$J,358.3,22275,1,4,0)
+576 ;;=4^C91.11
+577 ;;^UTILITY(U,$J,358.3,22275,2)
+578 ;;=^5001766
+579 ;;^UTILITY(U,$J,358.3,22276,0)
+580 ;;=C91.10^^71^914^53
+581 ;;^UTILITY(U,$J,358.3,22276,1,0)
+582 ;;=^358.31IA^4^2
+583 ;;^UTILITY(U,$J,358.3,22276,1,3,0)
+584 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+585 ;;^UTILITY(U,$J,358.3,22276,1,4,0)
+586 ;;=4^C91.10
+587 ;;^UTILITY(U,$J,358.3,22276,2)
+588 ;;=^5001765
+589 ;;^UTILITY(U,$J,358.3,22277,0)
+590 ;;=C92.11^^71^914^54
+591 ;;^UTILITY(U,$J,358.3,22277,1,0)
+592 ;;=^358.31IA^4^2
+593 ;;^UTILITY(U,$J,358.3,22277,1,3,0)
+594 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+595 ;;^UTILITY(U,$J,358.3,22277,1,4,0)
+596 ;;=4^C92.11
+597 ;;^UTILITY(U,$J,358.3,22277,2)
+598 ;;=^5001793
+599 ;;^UTILITY(U,$J,358.3,22278,0)
+600 ;;=C92.10^^71^914^55
+601 ;;^UTILITY(U,$J,358.3,22278,1,0)
+602 ;;=^358.31IA^4^2
+603 ;;^UTILITY(U,$J,358.3,22278,1,3,0)
+604 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+605 ;;^UTILITY(U,$J,358.3,22278,1,4,0)
+606 ;;=4^C92.10
+607 ;;^UTILITY(U,$J,358.3,22278,2)
+608 ;;=^5001792
+609 ;;^UTILITY(U,$J,358.3,22279,0)
+610 ;;=D47.1^^71^914^56
+611 ;;^UTILITY(U,$J,358.3,22279,1,0)
+612 ;;=^358.31IA^4^2
+613 ;;^UTILITY(U,$J,358.3,22279,1,3,0)
+614 ;;=3^Chronic Myeloproliferative Disease
+615 ;;^UTILITY(U,$J,358.3,22279,1,4,0)
+616 ;;=4^D47.1
+617 ;;^UTILITY(U,$J,358.3,22279,2)
+618 ;;=^5002256
+619 ;;^UTILITY(U,$J,358.3,22280,0)
+620 ;;=C82.69^^71^914^57
+621 ;;^UTILITY(U,$J,358.3,22280,1,0)
+622 ;;=^358.31IA^4^2
+623 ;;^UTILITY(U,$J,358.3,22280,1,3,0)
+624 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+625 ;;^UTILITY(U,$J,358.3,22280,1,4,0)
+626 ;;=4^C82.69
+627 ;;^UTILITY(U,$J,358.3,22280,2)
+628 ;;=^5001530
+629 ;;^UTILITY(U,$J,358.3,22281,0)
+630 ;;=C82.60^^71^914^58
+631 ;;^UTILITY(U,$J,358.3,22281,1,0)
+632 ;;=^358.31IA^4^2
+633 ;;^UTILITY(U,$J,358.3,22281,1,3,0)
+634 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+635 ;;^UTILITY(U,$J,358.3,22281,1,4,0)
+636 ;;=4^C82.60
+637 ;;^UTILITY(U,$J,358.3,22281,2)
+638 ;;=^5001521
+639 ;;^UTILITY(U,$J,358.3,22282,0)
+640 ;;=D56.2^^71^914^59
+641 ;;^UTILITY(U,$J,358.3,22282,1,0)
+642 ;;=^358.31IA^4^2
+643 ;;^UTILITY(U,$J,358.3,22282,1,3,0)
+644 ;;=3^Delta-Beta Thalassemia
+645 ;;^UTILITY(U,$J,358.3,22282,1,4,0)
+646 ;;=4^D56.2
+647 ;;^UTILITY(U,$J,358.3,22282,2)
+648 ;;=^340496
+649 ;;^UTILITY(U,$J,358.3,22283,0)
+650 ;;=D75.9^^71^914^60
+651 ;;^UTILITY(U,$J,358.3,22283,1,0)
+652 ;;=^358.31IA^4^2
+653 ;;^UTILITY(U,$J,358.3,22283,1,3,0)
+654 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+655 ;;^UTILITY(U,$J,358.3,22283,1,4,0)
+656 ;;=4^D75.9
+657 ;;^UTILITY(U,$J,358.3,22283,2)
+658 ;;=^5002393
+659 ;;^UTILITY(U,$J,358.3,22284,0)
+660 ;;=D59.0^^71^914^63
+661 ;;^UTILITY(U,$J,358.3,22284,1,0)
+662 ;;=^358.31IA^4^2
+663 ;;^UTILITY(U,$J,358.3,22284,1,3,0)
+664 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+665 ;;^UTILITY(U,$J,358.3,22284,1,4,0)
+666 ;;=4^D59.0
+667 ;;^UTILITY(U,$J,358.3,22284,2)
+668 ;;=^5002323
+669 ;;^UTILITY(U,$J,358.3,22285,0)
+670 ;;=D59.2^^71^914^64
+671 ;;^UTILITY(U,$J,358.3,22285,1,0)
+672 ;;=^358.31IA^4^2
+673 ;;^UTILITY(U,$J,358.3,22285,1,3,0)
+674 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
